CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer


The majority of ovarian cancers are diagnosed at advanced stages, and there are furthermore few therapeutic options for ovarian cancer patients. Though in-vitro knockout studies, and in-vivo expression level studies a research group led by Dr Benjamin Bitler have identified CBX2 as a important driver in ovarian cancer progression. The researchers aim to target CBX2 as a novel treatment for ovarian cancer to provide a treatment option to advanced stage ovarian cancer patients.

For Information, Contact:
Doreen Molk
University of Colorado
Benjamin Bitler
Lindsay Wheeler
Disease Areas:
For inquiries, email: cuinnovations@cuanschutz.edu.     © 2024. All Rights Reserved. Powered by Inteum